Feed GILD
GI

Gilead Sciences GILD NASDAQ · Healthcare · United States

$166.43 -0.06% -$0.10

Market cap
$206.6B
Enterprise value
$226.3B
P/E
-
Forward P/E
-
PEG
0.0x
P/S
6.7x
P/FCF
15.0x
EV/EBITDA
175.2x
ROIC
42.7%
Gross margin
79.9%
Net margin
-12.5%
Dividend yield
1.95%
Payout ratio
-
Net debt/EBITDA
15.3x
Beta
0.37
Free float
99.8%

About the company

Gilead Sciences, Inc. (GILD) is an American biopharmaceutical company specializing in research, development, and manufacturing of pharmaceuticals in the field of infectious diseases, viral diseases, and chronic conditions, such as HIV/AIDS, hepatitis C, hepatitis B, and more. The company is renowned for its innovative treatment approaches and drugs that have a significant impact on improving the quality of life for patients worldwide. Gilead Sciences is actively engaged in research and collaborates with academic institutions and healthcare organizations to discover new therapies and medications. With successful products and a strong research background, Gilead Sciences, Inc. has the potential for further innovations and expanding its pharmaceutical portfolio. Investing in Gilead Sciences, Inc. (GILD) shares may present an interesting choice for investors who follow the pharmaceutical sector and seek a company with a track record of successful products and commitment to combating serious diseases.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Daniel O'Day

Employees

17,000

Headquarters

Foster City

Valuation

Is today's price reasonable?

  • What to watch: The share price is above the Bulios Fair Price.

Growth and estimates

Is it growing, and what comes next?

  • What speaks for it: Earnings per share grew by 23% a year over the last 3 years.
  • What to watch: Revenue grew by only 2.6% a year over the last 3 years.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

  • What speaks for it: It earns 43 USD a year on every 100 USD of invested capital.
  • What speaks for it: Out of every 100 USD of revenue, 44 USD is left as free cash.
  • What to watch: The company made a loss over the last 12 months.

Financial health

Can it carry its debt?

  • What to watch: Repaying its net debt would take 15.3 years of operating profit.

Capital and dividends

What does the company do with the money it earns?

  • What speaks for it: It has raised its dividend 10 years in a row.

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy